Symbios Technologies, a US-based water treatment technology developer, is commercialising its Tubular Plasma Reactor TPR4000 advanced plasma oxidation system for fluid treatment.
The system is intended for applications in manufacturing, healthcare, utility, and oil and gas vertical markets.
“The TPR is the first-of-its-kind multi-modal oxidation system that combines electricity and air to achieve both hydrogen- and oxygen-based oxidation chemistries, without added chemicals,” Justin Bzdek, president and CEO at Symbios, said.
The Symbios TPR4000 is being advanced under Phase II and Phase IIB supplement National Science Foundation’s Small Business Innovation Research (NSF SBIR) grants along with other grants and industry investment.
Through non-thermal, homogeneous, distributed plasma discharge directly in water via its patented design, the TPR4000 achieves rapid disinfection and reduction of biochemical and chemical oxygen demand (BOD and COD) with higher efficacy and lower cost than other advanced oxidation processes without waste streams.
Combining the best of UV, ozone, peroxide, and chemical oxidation technologies, the Symbios TPR technology has been tested for efficacy in the food and beverage, healthcare, power plant, fracking wastewater treatment, and other industrial and municipal applications.
“The NSF’s support of science and technology start-ups with non-dilutive grants through the SBIR programme is critical to the success innovative companies like Symbios,” said Bzdek.
Symbios will be exhibiting its technology in the NSF SBIR Programme Pavilion, booth 5725, at the WEFTEC trade show in New Orleans.